End-of-Life Care Requires Caution with Use of Continuous Glucose Monitoring

Wang, Ray; Foskey, Rebecca; Barmanray, Rahul; Le, Brian; Fourlanos, Spiros

doi:10.1089/jpm.2021.0271

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also important to consider patient and caregiver preferences, the stage of end-of-life care, and the level of experience of the medical and nursing staff. 59 The IDF specifies that the threshold for continuing glucose monitoring in patients receiving end-of-life care should be high and only considered under unique circumstances (eg, beginning of corticosteroids known for their hyperglycemic effects) and when the risk of hypoglycemia is specifically high (eg, in case of important nutritional problems). 14 In functionally dependent patients with intermediate health (eg, with multiple comorbidities), the use of CGM is useful to prevent unrecognized hypoglycemia episodes, especially in individuals on insulin regimen or those who have difficulties with fingerstick monitoring.…”

Section: Dovepress 1697mentioning

confidence: 99%

Management of Glucose-Lowering Therapy in Older Adults with Type 2 Diabetes: Challenges and Opportunities

Doucet,

Gourdy,

Meyer

et al. 2023

CIA

View full text Add to dashboard Cite

The population of older adults (≥65 years) with type 2 diabetes mellitus (T2DM) is diverse, encompassing individuals with varying functional capabilities, living arrangements, concomitant medical conditions, and life expectancies. Hence, their categorization into different patient profiles (ie, good health, intermediate health, poor health) may aid in clinical decision-making when establishing glycemic goals and pharmacological treatment strategies. Further granularity in assessing each patient profile through interdisciplinary collaboration may also add precision to therapeutic and monitoring decisions. In this review, we discuss with a multidisciplinary approach how to deliver the best benefit from advanced diabetes therapies and technologies to older adults with T2DM according to each patient profile. There remain however several areas that deserve further research in older adults with T2DM, including the efficacy and safety of continuous glucose monitoring and automated insulin delivery systems, the switch to once-weekly insulin, the effectiveness of multidisciplinary care models, and the use of supported telemedicine and remote blood glucose monitoring in the oldest-old (≥85 years) who particularly require the assistance of others.

show abstract

Section: Dovepress 1697mentioning

confidence: 99%